Login
Amgen NASDAQ: AMGN
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It offers products for the treatment of oncology/hematology, cardiovascular, inflammation, bone health, nephrology, and neuroscience
| Name | Amgen |
| Ticker | AMGN |
| Exchange | NASDAQ |
| Sector | Health Care |
| Industry | Biopharmaceuticals |
|
Price
52W Low/High |
224.92
182.24 / 260.95 |
| Momentum | Neutral |
| Market cap | 131 B |
| 1Y Total Return |
15.02%
Below Average |
| 1Y Volatility |
37.06%
Low Risk |
Relative Strength Index : Attempt to identify overbought (above 80) and oversold (below 20) conditions
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It offers products for the treatment of oncology/hematology, cardiovascular, inflammation, bone health, nephrology, and neuroscience
Details
| Ticker | AMGN |
| Name | Amgen |
| ISIN | US0311621009 |
| CUSIP | 031162100 |
| Exchange | NASDAQ |
| Sector | Health Care |
| Industry | Biopharmaceuticals |
| Country | USA |
| Currency | U.S. Dollar |
| In Index(ices) |
|
Share as of 2/26/21
| Close Price | 224.92 |
| 52W Low/High | 182.24 / 260.95 |
| Market cap | 131 B |
| 1Y Total Return |
15.02%
Below Average |
| 1Y Volatility |
37.06%
Low Risk |
| Beta | 0.98 |
| PE (trailing) |
18.27
Below Average |
| 12M Dividends | 6.4 |
| Last Dividend Date | 11/13/20 |
| Dividend Yield | 2.85% |
Fin. Strength
| Net Profit Margin | 28.6% |
| Cash from Op. / Cur. Liabilities | 0.90 |
| Diluted Earnings / Share | 12.31 |
| ROE | 76.1% |
| ROIC | 19.8% |
| Price / Revenue | 5.2 |
| Price / Book | 14.1 |
| Price / CF | 12.6 |
| Current Ratio | 1.8 |
| Cur.Liabilities / Tot.Liabilities | 0.2 |
| Financial Leverage | 3.51 |
| in Mils USD |
rolling-year up to December
|
||||||
|---|---|---|---|---|---|---|---|
| Income Statement | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
| Revenue |
25,424
|
23,362
|
23,747
|
22,849
|
22,991
|
21,662
|
|
| Gross Profit |
19,265
|
19,006
|
19,646
|
18,780
|
18,829
|
17,435
|
|
| R&D |
4,207
|
4,116
|
3,737
|
3,562
|
3,840
|
4,070
|
|
| EBITDA |
12,996
|
12,633
|
12,883
|
12,856
|
12,528
|
11,181
|
|
| Operating Income |
9,139
|
9,674
|
10,263
|
9,973
|
9,794
|
8,470
|
|
| Net Income exc. Extra |
7,264
|
7,842
|
8,394
|
1,979
|
7,722
|
6,939
|
|
| per Share | |||||||
| Diluted avg Shares |
590
|
609
|
665
|
735
|
754
|
766
|
|
| EPS exc. Extra |
12.31
|
12.88
|
12.62
|
2.69
|
10.24
|
9.06
|
|
| Dividend |
6.40
|
5.80
|
5.28
|
4.60
|
4.00
|
3.16
|
|
| Div. Yield (an.) |
2.78%
|
2.41%
|
2.71%
|
2.65%
|
2.74%
|
1.95%
|
|
| Balance Sheet | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
| Total Assets |
62,948
|
59,707
|
66,416
|
79,954
|
77,626
|
71,449
|
|
| Cash, Eq & Invt ShortTerm |
10,647
|
8,911
|
29,304
|
41,678
|
38,085
|
31,382
|
|
| Total Current Assets |
21,144
|
18,440
|
37,618
|
49,476
|
46,010
|
38,515
|
|
| Total Non-Current Assets |
41,804
|
41,267
|
28,798
|
30,478
|
31,616
|
32,934
|
|
| Intangibles |
31,276
|
34,116
|
22,142
|
23,370
|
25,030
|
26,428
|
|
| Total Liabilities |
53,539
|
50,034
|
53,916
|
54,713
|
47,751
|
43,366
|
|
| Total Current Liabilities |
11,653
|
12,835
|
13,488
|
9,020
|
11,204
|
8,664
|
|
| Long Term Debt |
41,886
|
37,199
|
40,428
|
45,693
|
36,547
|
34,702
|
|
| Shareholder equity |
9,409
|
9,673
|
12,500
|
25,241
|
29,875
|
28,083
|
|
| Cash Flow | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
| Cash from Operations |
10,497
|
9,150
|
11,296
|
11,177
|
10,354
|
9,731
|
|
| Depreciation |
3,601
|
2,206
|
1,946
|
1,955
|
2,105
|
2,108
|
|
| Cash from Investing |
-5,401
|
5,709
|
14,339
|
-4,024
|
-8,658
|
-5,547
|
|
| Capex |
608
|
618
|
738
|
664
|
738
|
320
|
|
| Cash from Financing |
-4,867
|
-15,767
|
-22,490
|
-6,594
|
-2,599
|
-3,771
|
|
| Stock Issued |
-3,486
|
-7,702
|
-17,794
|
-3,160
|
-2,965
|
-1,867
|
|
| Debt (LT) Issued |
2,464
|
-4,514
|
-1,121
|
71
|
3,593
|
1,065
|
|
| Free Cash Flow |
9,123
|
8,902
|
14,673
|
812
|
11,702
|
10,272
|
|
| Ratios | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
| Net Profit Margin |
28.6%
|
33.6%
|
35.3%
|
8.7%
|
33.6%
|
32.0%
|
|
| NCFO / Op.Income |
114.9%
|
94.6%
|
110.1%
|
112.1%
|
105.7%
|
114.9%
|
|
| Current Ratio |
1.8
|
1.4
|
2.8
|
5.5
|
4.1
|
4.4
|
|
| Financial Leverage D/E |
3.51
|
3.09
|
2.71
|
1.40
|
1.16
|
1.12
|
|
| Return on Capital Avg |
19.8%
|
20.8%
|
17.0%
|
2.8%
|
14.0%
|
12.6%
|
|
| Return on Shareholder Equity |
76.1%
|
70.7%
|
44.5%
|
7.2%
|
26.6%
|
25.8%
|
|
Fundamentals
No documents are available for the moment, please check back soon, or save the asset to be notified when documents are available